About
Shulov Innovative Science (SIS) is an advanced clinical-stage biopharmaceutical company focusing on developing New Chemical Entities (NCE’s) for a variety of therapeutic uses. The NCE’s are short synthetic peptides with a unique pharmacological activity of combined potency as an effective anti-inflammatory, anti-viral, and analgesic agent. The NCE’s under development are short synthetic peptides branded as ZEP-3 and ZEP-4, and both molecules possess the unique biological activity and potent therapeutic use for a wide range of clinical indications.
The company completed a Phase II clinical study in Herpes Labialis (Cold sores) and has approached the FDA in preparation for a pre-IND meeting to secure an IND submission for an advanced Phase III clinical trial in Herpes Labialis patients in the US. It is the next step towards regulatory approval for the marketing and commercialization of its lead compound. In addition, SIS conducts a Phase II clinical study in Atopic Dermatitis (AD), a common and underserved dermatological disorder, in 9 clinical sites at the leading dermatology departments at hospitals and community clinics in Israel.
SIS is developing additional clinical indications such as Herpes Zoster, Genital Herpes, Burns, and Lung Inflammation. Pre-clinical work is complete, and the company is ready to start a Phase I/II study on each of these indications.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is SIS Shulov Innovative Science's primary focus?
- SIS Shulov Innovative Science is an advanced clinical-stage biopharmaceutical company focused on developing New Chemical Entities (NCEs) for various therapeutic uses, particularly in dermatology.
- What are the lead compounds under development by SIS Shulov Innovative Science?
- The lead compounds under development by SIS Shulov Innovative Science are short synthetic peptides branded as ZEP-3 and ZEP-4.
- What clinical study has SIS Shulov Innovative Science completed for Herpes Labialis?
- SIS Shulov Innovative Science has completed a Phase II clinical study for Herpes Labialis (Cold sores).
- What is SIS Shulov Innovative Science's next step for its Herpes Labialis compound in the US?
- SIS Shulov Innovative Science has approached the FDA for a pre-IND meeting to prepare for an IND submission for an advanced Phase III clinical trial in Herpes Labialis patients in the US.
- What other clinical study is SIS Shulov Innovative Science currently conducting?
- SIS Shulov Innovative Science is conducting a Phase II clinical study for Atopic Dermatitis (AD) across 9 clinical sites in Israel.
- What additional clinical indications is SIS Shulov Innovative Science developing?
- SIS Shulov Innovative Science is developing additional clinical indications including Herpes Zoster, Genital Herpes, Burns, and Lung Inflammation, with pre-clinical work completed and readiness to start Phase I/II studies.
- When was SIS Shulov Innovative Science founded?
- SIS Shulov Innovative Science was founded in January 1985.
- How many employees does SIS Shulov Innovative Science currently have?
- SIS Shulov Innovative Science has 31 employees.
- What is the current funding stage of SIS Shulov Innovative Science?
- According to startupim data, SIS Shulov Innovative Science is currently in the 'Pre-Funding' stage.